By VETTAPHARMA reporter: has informed the Board of Novartis India Limited (NIL) that it has entered into an agreement with ChrysCapital for the transfer of its entire 70.68% shareholding in Novartis India Limited.
The proposed transaction involves the sale of Novartis AG’s full promoter stake in NIL to ChrysCapital. Upon completion of the transaction, ChrysCapital will assume ownership of the 70.68% equity stake currently held by Novartis AG.
As required under applicable Indian regulations, the transaction will trigger a mandatory open offer for up to 26% of the expanded voting share capital of Novartis India Limited from public shareholders.
Novartis stated that this development follows the previously announced strategic review of its shareholding in Novartis India Limited. The company also clarified that Novartis will continue to maintain its presence in India through other entities and operations.
The completion of the transaction remains subject to customary closing conditions and regulatory approvals.
Source credit:
- Novartis AG. (2026, February 20). Novartis AG has informed the Board of Novartis India Limited (NIL) that Novartis AG has entered into an agreement with ChrysCapital, one of India’s largest private equity firms, to transfer its shareholding in NIL. Click here
